Douglas Pharmaceuticals Limited

The University of Manchester

Ian Hampson

Lynne Hampson

Peter William Surman

Fergus Cameron Binnie

Provided herein are methods and compositions for treating and/or inhibiting the development or progression of conditions caused by, or associated with, Herpes Simplex Virus (HSV) infection. In particular, provided are compositions comprising lopinavir alone, or lopinavir and ritonavir, methods for their manufacture; and the use of said pharmaceutical compositions as a medicament. In particular, pharmaceutical compositions are provided for use in treating and/or inhibiting the progression of HSV related conditions.

Compositions comprising lopinavir and treatment of conditions

The present invention concerns pharmaceutical compositions formulated for dermal application comprising a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir:ritonavir is between 9:1 and 18:1. Such compositions are useful for treating, or preventing, skin cancers and premalignant dermal conditions.

Treatments

The present invention concerns pharmaceutical compositions formulated for topical application that are useful in the treatment of HPV-related pathologies and in particular the treatment of premalignant and malignant conditions of the cervix. The com-positions comprise a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir: ritonavir is between 9:1 and 18:1.

Lopinavir and ritonavir for the treatment of cervix disorders

Disclosed herein are compositions comprising lopinavir alone or in combination with ritonavir for use as a medicament in the treatment of cancer or benign proliferative disorders (warts) or in the prevention of the development of cancer. Pharmaceutical compositions formulated for topical application comprising a therapeutically effective amount of lopinavir or a therapeutically effective amount lopinavir and ritonavir in a pharmaceutically acceptable vehicle are also provided. Also disclosed are methods of treating a patient having an HPV related dysplasia of the cervix comprising administering to said patient a therapeutically effective dose of the disclosed pharmaceutical compositions.

Growing community of inventors

Manchester, United Kingdom

Ian Hampson